Cargando…
SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
Introduction - The combination of sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and glucocorticoid excess can trigger ketone production by reducing insulin secretion/sensitivity and stimulating glucosuria, glucagon production, and lipolysis. In addition, metabolic alkalosis caused by glucoc...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552005/ http://dx.doi.org/10.1210/js.2019-SAT-453 |
_version_ | 1783424502279962624 |
---|---|
author | Sagalla, Nicole Weaver, Anne Qamar, Ali Gratian, Lauren Crowley, Matthew |
author_facet | Sagalla, Nicole Weaver, Anne Qamar, Ali Gratian, Lauren Crowley, Matthew |
author_sort | Sagalla, Nicole |
collection | PubMed |
description | Introduction - The combination of sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and glucocorticoid excess can trigger ketone production by reducing insulin secretion/sensitivity and stimulating glucosuria, glucagon production, and lipolysis. In addition, metabolic alkalosis caused by glucocorticoid excess (via mineralocorticoid receptor activation) may combine with diabetic ketoacidosis (DKA) to create a mixed acid-base disorder, which can potentially obscure SGLT-2i-associated DKA. Case Description - A 45 year-old man with well-controlled type 2 diabetes on an SGLT-2i presented to the Emergency Room with edema, weakness, palpitations, polyuria/polydipsia, hypertension, and hyperglycemia. Exam was significant for a blood pressure of 195/111mmHg, moon facies, supraclavicular fat pad fullness, obese abdomen with violaceous striae, and reduced bilateral hip flexor weakness. He was found to have potassium 2.5mmol/L, glucose 296mg/dL, bicarbonate 28mmol/L, and anion gap 20mmol/L. Venous pH was 7.51, with pCO2 38mmHg. Beta-hydroxybutyrate was >8.0mmol/L (<0.40). Random cortisol was 59.1ug/dL (5-25ug/dL) and ACTH 313pg/mL (15-66pg/mL). 24hr Urine Cortisol was 1567mcg/24hrs (3.5-45mcg/24hrs). Pituitary MRI showed diffuse pituitary enlargement and a 7mm pituitary adenoma. The patient’s DKA was managed with IV fluids and insulin, and potassium was aggressively replaced. He underwent successful trans-sphenoidal pituitary adenoma resection, with positive ACTH staining on pathology. ACTH and cortisol 12 hours postoperatively were 78pg/mL and 15.1ug/dL, respectively, and continued to downtrend. On the second postoperative day, the patient developed severe anxiety, which improved with increased glucocorticoid supplementation. Conclusion - DKA is a rare side effect of SGLT-2i use, and even rarer in the setting of Cushing’s Disease. In this case, the patient’s underlying Cushing’s Disease likely contributed to the development of SGLT-2i-associated DKA and severe hypokalemia, while also obscuring the diagnosis by causing a concurrent metabolic alkalosis that normalized the pH and bicarbonate. The competing physiologic mechanisms at play led to this unusual presentation of SGLT-2i-associated DKA with an alkalotic pH and normal bicarbonate. |
format | Online Article Text |
id | pubmed-6552005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65520052019-06-13 SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease Sagalla, Nicole Weaver, Anne Qamar, Ali Gratian, Lauren Crowley, Matthew J Endocr Soc Neuroendocrinology and Pituitary Introduction - The combination of sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and glucocorticoid excess can trigger ketone production by reducing insulin secretion/sensitivity and stimulating glucosuria, glucagon production, and lipolysis. In addition, metabolic alkalosis caused by glucocorticoid excess (via mineralocorticoid receptor activation) may combine with diabetic ketoacidosis (DKA) to create a mixed acid-base disorder, which can potentially obscure SGLT-2i-associated DKA. Case Description - A 45 year-old man with well-controlled type 2 diabetes on an SGLT-2i presented to the Emergency Room with edema, weakness, palpitations, polyuria/polydipsia, hypertension, and hyperglycemia. Exam was significant for a blood pressure of 195/111mmHg, moon facies, supraclavicular fat pad fullness, obese abdomen with violaceous striae, and reduced bilateral hip flexor weakness. He was found to have potassium 2.5mmol/L, glucose 296mg/dL, bicarbonate 28mmol/L, and anion gap 20mmol/L. Venous pH was 7.51, with pCO2 38mmHg. Beta-hydroxybutyrate was >8.0mmol/L (<0.40). Random cortisol was 59.1ug/dL (5-25ug/dL) and ACTH 313pg/mL (15-66pg/mL). 24hr Urine Cortisol was 1567mcg/24hrs (3.5-45mcg/24hrs). Pituitary MRI showed diffuse pituitary enlargement and a 7mm pituitary adenoma. The patient’s DKA was managed with IV fluids and insulin, and potassium was aggressively replaced. He underwent successful trans-sphenoidal pituitary adenoma resection, with positive ACTH staining on pathology. ACTH and cortisol 12 hours postoperatively were 78pg/mL and 15.1ug/dL, respectively, and continued to downtrend. On the second postoperative day, the patient developed severe anxiety, which improved with increased glucocorticoid supplementation. Conclusion - DKA is a rare side effect of SGLT-2i use, and even rarer in the setting of Cushing’s Disease. In this case, the patient’s underlying Cushing’s Disease likely contributed to the development of SGLT-2i-associated DKA and severe hypokalemia, while also obscuring the diagnosis by causing a concurrent metabolic alkalosis that normalized the pH and bicarbonate. The competing physiologic mechanisms at play led to this unusual presentation of SGLT-2i-associated DKA with an alkalotic pH and normal bicarbonate. Endocrine Society 2019-04-30 /pmc/articles/PMC6552005/ http://dx.doi.org/10.1210/js.2019-SAT-453 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Neuroendocrinology and Pituitary Sagalla, Nicole Weaver, Anne Qamar, Ali Gratian, Lauren Crowley, Matthew SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease |
title | SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease |
title_full | SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease |
title_fullStr | SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease |
title_full_unstemmed | SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease |
title_short | SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease |
title_sort | sat-453 diabetic "ketoalkalosis" due to sglt2 inhibitor in the setting of cushing's disease |
topic | Neuroendocrinology and Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552005/ http://dx.doi.org/10.1210/js.2019-SAT-453 |
work_keys_str_mv | AT sagallanicole sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease AT weaveranne sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease AT qamarali sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease AT gratianlauren sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease AT crowleymatthew sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease |